Novartis AG is 124.9x more valuable than Ultragenyx Pharmaceutical Inc. by market capitalization ($282.64 B vs $2.26 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | RARE | NVS |
|---|---|---|
| Market cap | $2.26 B | $282.64 B |
| US-listed rank | #2014 | #47 |
| Revenue (latest FY) | $673.00M | - |
| Net income (latest FY) | -$575.00M | - |
| Net margin | -85.4% | - |
| SEC filings | 1,100 | 947 |
Novartis AG is 124.9x more valuable than Ultragenyx Pharmaceutical Inc. by market capitalization ($282.64 B vs $2.26 B).
Full pages: Ultragenyx Pharmaceutical Inc. and Novartis AG, or browse the full rankings.